• Corpus ID: 53467095

Efficacy and toxicity of concurrent radiochemotherapy with gemcitabine after transurethral resection of invasive bladder cancer

@inproceedings{Asadauskien2007EfficacyAT,
  title={Efficacy and toxicity of concurrent radiochemotherapy with gemcitabine after transurethral resection of invasive bladder cancer},
  author={Jolita Asadauskienė and Eduardas Aleknavi{\vc}ius and Asta Žilevi{\vc}ienė and Teresė Pipirienė Želvienė and Feliksas Jankevicius},
  year={2007}
}
Background. To evaluate the efficacy of combination of gemcitabine and radiotherapy in conservative treatment of invasive bladder cancer: toxicity, tolerance and possibilities of bladder preservation. Materials and methods. Fourteen patients with the invasive bladder cancer (pT2–pT4) were treated according to the protocol of clinical study. In all the cases transurethral resection was followed by radiation and chemotherapy. A total dose of 54–60 Gy of radiotherapy was delivered by daily… 

Figures and Tables from this paper

References

SHOWING 1-10 OF 15 REFERENCES
Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer.
TLDR
After transurethral resection for the conservative treatment of infiltrating bladder cancer, gemcitabine doses of up to 400 mg/m(2)/week seem to be safe in combination with cisplatin and radiotherapy in organ-sparing management.
Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trial.
  • E. Kent, H. Sandler, +5 authors D. Smith
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
TLDR
Twice-weekly gemcitabine with concurrent radiotherapy at 2 Gy/d to a total dose of 60 Gy is well-tolerated and there is a high rate of bladder preservation in this selected group of patients.
Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer.
TLDR
TURB followed by RT/RCT is an alternative treatment option to primary cystectomy for patients with muscle-invading bladder cancer and the addition of cisplatin or carboplatin leads to significantly more complete remissions and better survival.
Phase I study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer.
TLDR
The maximal tolerated dose for gemcitabine given once weekly during hypofractionated conformal radiotherapy to patients with locally advanced transitional cell carcinoma of the bladder was 150 mg/m(2), with a maximal recommended dose of 100 mg/ m(2).
Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study.
  • M. Housset, C. Maulard, +6 authors F. Baillet
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1993
TLDR
This neoadjuvant chemoradiotherapy combination, easy to implement and well tolerated even in elderly patients, provides a high complete response rate and may prove to be effective in inoperable patients and may be proposed as conservative treatment in patients with a complete response to the initial course of chemoradiation.
Bladder preservation by combined modality therapy for invasive bladder cancer.
  • L. Kachnic, D. Kaufman, +4 authors W. Shipley
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1997
TLDR
Combined modality therapy with TURBT, chemotherapy, radiation, and selection for organ-conservation by response has a 52% overall survival rate, similar to cystectomy-based studies for patients of similar age and clinical stages.
Invasive bladder cancer: treatment strategies using transurethral surgery, chemotherapy and radiation therapy with selection for bladder conservation.
TLDR
Bladder conservation trials using combined modality treatment approaches with selection for organ conservation by response of the tumor to initial treatment report overall 5-year survival rates of approximately 50%, and a 40-45% 5- year survival rate with the bladder intact.
Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer.
TLDR
A trimodality approach with bladder preservation based on the initial tumor response is, therefore, safe, with most long-term survivors retaining functional bladders.
Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results.
TLDR
TUR with RCT is a reasonable option for patients seeking an alternative to radical cystectomy and Ideal candidates are those with early-stage and unifocal tumors, in whom a complete TUR is accomplished.
Overview of bladder cancer trials in the Radiation Therapy Oncology Group
TLDR
The current RTOG protocol and its successor are directed toward better tolerated and potentially more effective chemotherapy regimens that may result in a high protocol compliance rate and, possibly, a higher overall survival rate.
...
1
2
...